Advanced search
Publication Cover
Structural Heart
The Journal of the Heart Team
Volume 4, 2020 - Issue 6
Journal homepage
159
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Aortic Stenosis and Amyloidosis: Underdiagnosed and Underreported

Brett W. Sperrya Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA;b University of Missouri – Kansas City, Kansas City, Missouri, USACorrespondence[email protected]
View further author information
, MD &
Kyle Lehenbauera Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA;b University of Missouri – Kansas City, Kansas City, Missouri, USAView further author information
, MD
Pages 515-517 | Published online: 20 Oct 2020

References

  • Sperry BW, Tang WHW. Amyloid heart disease: genetics translated into disease-modifying therapy. Heart. 2017;103(11):812–817. doi:10.1136/heartjnl-2016-309914.
  • Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi:10.1056/NEJMoa1805689.
  • Sperry BW, Vranian MN, Hachamovitch R, et al. Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc. 2016;5(3):e002877. doi:10.1161/JAHA.115.002877.
  • Ternacle J, Krapf L, Mohty D, et al. Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2019;74(21):2638–2651. doi:10.1016/j.jacc.2019.09.056.
  • Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–1715. doi:10.1056/NEJMoa1816885.
  • Dorbala S, Bokhari S, Miller EJ, Bullock-Palmer R, Soman P, Thompson R. 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. ASNC Pract Points. https://www.asnc.org/practicepoints. Released February 27, 2019. Accessed October 16, 2020.
  • Nitsche C, Aschauer S, Kammerlander AA, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. Feb 20, 2020. doi:10.1002/ejhf.1756.
  • Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9(8). doi:10.1161/CIRCIMAGING.116.005066.
  • Scully PR, Treibel TA, Fontana M, et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71(4):463–464. doi:10.1016/j.jacc.2017.11.037.
  • Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–2887. doi:10.1093/eurheartj/ehx350.
  • Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med. 2008;40(3):232–239. doi:10.1080/07853890701842988.
  • Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612.
  • Sperry BW, Saeed IM, Raza S, Kennedy KF, Hanna M, Spertus JA. Increasing rate of hospital admissions in patients with amyloidosis (from the national inpatient sample). Am J Cardiol. 2019;124(11):1765–1769. doi:10.1016/j.amjcard.2019.08.045.
  • Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759–2767. doi:10.1093/eurheartj/ehaa170.
  • Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly Black Americans. N Engl J Med. 2015;372(1):21–29. doi:10.1056/NEJMoa1404852.
  • Scully PR, Patel KP, Saberwal B, et al. Identifying cardiac amyloid in aortic stenosis: ECV quantification by CT in TAVR patients. JACC Cardiovasc Imaging. 2020. doi:10.1016/j.jcmg.2020.05.029.
  • Rosenblum H, Masri A, Narotsky DL, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail. Jul 30, 2020. doi:10.1002/ejhf.1974.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.